By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Acucela Inc. 

1301 Second Avenue
Suite 1900, 19th Floor
Seattle  Washington  98101-3805  U.S.A.
Phone: 206-805-8300 Fax: 206-805-8301

Acucela Inc. is a clinical-stage biotechnology company focused on leveraging promising science in visual cycle modulation (VCM) to develop new methods for treating blinding eye diseases that affect tens of millions of people worldwide. The company’s orally-delivered VCM therapies, which selectively target cells within the retina to protect visual acuity, have the potential to be used to treat several devastating eye diseases, including dry age-related macular degeneration (AMD), retinopathy of prematurity, Stargardt disease and diabetic retinopathy. Acucela is also developing, with Otsuka Pharmaceutical, Rebamipide ophthalmic suspension, a Phase 3 product candidate for dry eye.

For more information, please visit

Key Statistics

Ownership: Public

Web Site: Acucela
Symbol: AUCL


Company News
Acucela (AUCL) Granted New Patent Covering Method Of Use For Emixustat Hydrochloride 9/11/2017 8:27:07 AM
Acucela (AUCL) Initiates Phase 2a Study Of Emixustat Hydrochloride Addressing Patients With Stargardt Disease 1/27/2017 10:09:18 AM
Acucela (AUCL) Receives Orphan Drug Designation From The FDA For The Treatment Of Stargardt Disease 1/6/2017 11:27:56 AM
Acucela (AUCL) Secures Option To Exclusively Acquire Novel Retinal Technology 12/14/2016 10:24:26 AM
Acucela (AUCL) Announces Official Name Of Acucela Japan As Kubota Pharmaceutical Holdings Co., Ltd. 8/10/2016 9:51:18 AM
Announcement Regarding the News Coverage Concerning An Inquiry On Trades Of Acucela (AUCL) Shares 6/22/2016 11:18:35 AM
Amid Insider Trader Investigations, Acucela (AUCL) and Otsuka Pharma Kill Glaucoma Drug Deal After Failed Trial 6/14/2016 6:16:47 AM
Acucela Announces Top-Line Results From Phase 2b/3 Clinical Trial Of Emixustat 5/26/2016 11:32:55 AM
Acucela Initiates Phase 2 Clinical Trial Addressing Proliferative Diabetic Retinopathy 5/9/2016 11:47:40 AM
Acucela To Present At Association for Research in Vision & Ophthalmology 2016 Annual Meeting’s Education Courses In Seattle 4/22/2016 8:22:29 AM